UroToday

ASCO GU 2026: OPTIMAS: A Phase II Randomized, Decentralized, De-Escalation Trial in Patients with mHSPC Achieving Optimal PSA Response

The 2026 ASCO GU Annual Symposium was host to a trials-in-progress prostate cancer poster session. Dr. Umang Swami presented ...
UroToday

ASCO GU 2026: Discussant: The Era of ADCs for Urothelial Carcinoma Continues

The 2026 GU ASCO annual meeting featured a urothelial carcinoma session and a discussant presentation by Dr. Tyler F. Stewart ...
UroToday

ASCO GU 2026: Discussant: Prevention to Progression – Targeting Foundational Biology in RCC

The 2026 GU ASCO annual meeting featured a renal cell carcinoma session and a discussant presentation by Dr. Beckermann, discussing three abstracts, “Belzutifan + lenvatinib versus cabozantinib for ...
UroToday

ASCO GU 2026: A Phase II Trial of Cabozantinib in Relapsed Refractory Germ Cell Tumors

The 2026 GU ASCO annual meeting featured a testicular cancer session and a presentation by Dr. Jennifer King discussing a ...
UroToday

ASCO GU 2026: REJOICE-PanTumor01: A Phase 2 Signal-Seeking Study of Raludotatug Deruxtecan in Patients with Advanced or Metastatic Gynecologic or Genitourinary Tumors

(UroToday.com) The 2026 GU ASCO annual meeting featured a kidney cancer trials in progress session and a presentation by Dr. Laurence Albiges discussing REJOICE-PanTumor01, a phase 2 signal-seeking ...
UroToday

ASCO GU 2026: LUNAR: Safety and Efficacy Evaluation of Nadofaragene Firadenovec Instilled into the Renal Pelvis in Subjects with Low-Grade UTUC: A Single-Arm, Open-Label Phase ...

Safety and efficacy evaluation of nadofaragene firadenovec instilled into the renal pelvis in subjects with low-grade upper tract urothelial carcinoma (LG-UTUC): A single-arm, open-label phase 1/2 ...
UroToday

Curium Announces Pharmacokinetics and Dosimetry Data for Investigational Lutetium-177 Zadavotide Guraxetan in Metastatic Castration-Resistant Prostate Cancer at ASCO GU 2026

These data represent the first published dosimetry data for our investigational formulation of Lu-177 zadavotide guraxetan, with projected mean cumulative renal doses remaining low for a six-cycle ...
UroToday

ASCO GU 2026: Discussant: miR-371a-3p for MRD Detection in Clinical Stage I Testicular Germ Cell Tumors

Based on the NCCN 1.2026 guidelines for the management of CSI seminoma, surveillance is strongly preferred for pT1-pT3 tumors, and the NCCN does not recommend risk-adapted treatment for CSI seminoma ...
UroToday

ASCO GU 2026: Biomarker Analysis from the Phase 2 LITESPARK-013 Study of Two Different Belzutifan Doses in Participants with Advanced Clear Cell RCC

Patients with advanced clear cell RCC whose disease progressed after 1-3 prior systemic therapies (including an anti–PD- [L]1 therapy) were randomly assigned 1:1 to belzutifan 200 mg or 120 mg daily: ...
UroToday

ASCO 2025: Trials-in-Progress – XALute: Phase 3 Study of Xaluritamig vs Investigator’s Choice of Cabazitaxel or Second Androgen Receptor-Directed Therapy in Post-Taxane ...

ASCO 2025, prostate cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), XALute Study, Xaluritamig, Cabazitaxel, Xaluritamig versus Cabazitaxel or Second Androgen Receptor-Directed Therapy ...
UroToday

The Latest Research in Erectile Dysfunction

Development of a Risk Predictive Model for Erectile Dysfunction at 12 Months after COVID-19 Recovery: A Prospective Observational Study - Beyond the Abstract ...
UroToday

Clinical Trials

Carboplatin is a second-generation platinum-based chemotherapeutic agent developed to retain the antitumor efficacy of cisplatin while substantially reducing renal, neurologic, and gastrointestinal ...